Preclinical and clinical development of cyclin-dependent kinase modulators.
about
Interferon regulatory factor 6 promotes cell cycle arrest and is regulated by the proteasome in a cell cycle-dependent mannerGenomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridolTargeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitorsMurine models and cell lines for the investigation of pheochromocytoma: applications for future therapies?The cyclin-dependent kinases cdk2 and cdk5 act by a random, anticooperative kinetic mechanismFlavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol dispositionPoldip2 knockout results in perinatal lethality, reduced cellular growth and increased autophagy of mouse embryonic fibroblastsThe unusual mechanism of inhibition of the p90 ribosomal S6 kinase (RSK) by flavonol rhamnosides.A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignanciesAntineoplastic agents from natural sources: achievements and future directions.Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine.p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol.A high-performance liquid chromatography method using ultraviolet detection for the quantitation of flavopiridol from human plasma.Protein fingerprints of anti-cancer effects of cyclin-dependent kinase inhibition: identification of candidate biomarkers using 2-D liquid phase separation coupled to mass spectrometry.Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrestFlavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.Flavopiridol inhibits P-TEFb and blocks HIV-1 replication.The CDK9/cyclin T1 subunits of P-TEFb in mouse oocytes and preimplantation embryos: a possible role in embryonic genome activation.Cyclin-dependent kinase inhibitors: novel anticancer agents.Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo.Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status.The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cellsTargeted therapies for gastric cancer: current status.Small molecule modulators of cyclin-dependent kinases for cancer therapy.The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor.Fluoroquinolone-mediated inhibition of cell growth, S-G2/M cell cycle arrest, and apoptosis in canine osteosarcoma cell lines.Identification of homeodomain proteins, PBX1 and PREP1, involved in the transcription of murine leukemia virus.Novel pharmacological agents in clinical development for solid tumours.Anticancer Alkaloids from Trees: Development into Drugs.Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.Targeting the cell cycle for cancer therapy.Defects in G1-S cell cycle control in head and neck cancer: a review.Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.6,7-di-O-acetylsinococuline (FK-3000) induces G2/M phase arrest in breast carcinomas through p38 MAPK phosphorylation and CDC25B dephosphorylation.Antiproliferative effect of the jararhagin toxin on B16F10 murine melanomaRB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer.Cyclin-dependent protein kinases as therapeutic drug targets for antimalarial drug development.
P2860
Q24307484-055EAA85-F015-4F67-B90C-F7C0EDB58B00Q24805832-FC8DE018-48BC-4985-81D3-D4906F3BDAB9Q26827580-2CA0992B-713F-42D8-8DDF-EC7DB7A67744Q26828446-E421F85D-D16F-423F-AD2D-2371FCEEDCEDQ27635427-9295D500-915B-4201-A9F8-7B8FA8DE785BQ28475976-9DB84372-32A1-4954-8E75-EE03AEAC00BAQ28512750-1DBC6497-EEE3-41EE-8F47-AF5E90AF997BQ30412077-7F0D3FA8-60C7-422B-813D-C779A407A191Q30431388-F8CCF70F-404C-4120-ADD0-EBB2D562B883Q30659806-73BCA5FD-C0EF-44BC-866D-6D0A3F9AA866Q30660667-1EE7084C-8F88-4264-A479-6F37CC896729Q30847612-3BE82601-4BB1-487E-95DC-09557FB014A2Q30847916-6D85950A-72A3-4817-B8F2-5FE7ABC90895Q33219920-6D296BB3-D41E-447A-B2C8-FC1381F0DBFBQ33241207-E4425E18-CC1E-4818-AE61-36AC43141213Q33627721-62F053EA-308F-48C4-AFEA-E2AB9530CD7CQ33786955-596EB811-9E14-4BB5-9891-0CFF3C81E334Q33872754-4B67F166-6C97-417E-9455-957DB4A1C391Q33910799-D2FCCB75-6FA5-4710-B8DD-B453002A020DQ33922363-2DA2E827-FF81-4BE1-9BC2-27015DC7CB93Q34075028-CCD2413D-5D19-47F9-A439-25494A2BC508Q34082542-1CB7907E-09BF-46C0-8D2F-9B2AC98192C6Q34090992-1D58602E-683A-45A8-AFD4-D4E3A818A3EAQ34178106-70C59E63-18EF-4659-9AFA-6573AC0AC218Q34205672-C7B8BD87-08C9-4395-9257-65797595B65BQ34293568-BBF4B370-F5D1-4AAD-9748-CE726877DE54Q34293622-BAA64EE2-B912-455F-8CC0-27FEEB15CE83Q34335802-1FECDE40-8041-4B0B-BC12-80666F39096DQ34395559-BE5952BD-BE91-4427-95BF-AB2332E1E0D1Q34463374-A490DFA8-E9A8-4925-B3EF-98C93EDBCC31Q34481861-DE90A196-8A61-4A09-8FCF-17E8D16CA498Q34549113-6D107EC7-1620-4720-AB1E-4D45CB93A6F2Q34615632-F5F1A12F-2B78-4231-9CF3-4A8B59E00EB8Q34728354-84A99439-142E-4F98-A791-57E8ED0A74CBQ34733424-D8F48E53-32B3-4AC4-B3CE-045EFBC54C22Q34754350-24F34AFC-61BB-44D8-BF6F-87A8FBEDD56CQ34775823-3BE389F7-CD74-4970-98FF-069A49E23859Q34896206-11F14953-BA9A-4791-8C40-CA0A3B187EB5Q34935948-DBA5E440-3763-415E-BB23-D33F28DA8889Q35056015-9BB9A7F7-4D73-4A0D-917A-00A90D234AAB
P2860
Preclinical and clinical development of cyclin-dependent kinase modulators.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Preclinical and clinical development of cyclin-dependent kinase modulators.
@ast
Preclinical and clinical development of cyclin-dependent kinase modulators.
@en
type
label
Preclinical and clinical development of cyclin-dependent kinase modulators.
@ast
Preclinical and clinical development of cyclin-dependent kinase modulators.
@en
prefLabel
Preclinical and clinical development of cyclin-dependent kinase modulators.
@ast
Preclinical and clinical development of cyclin-dependent kinase modulators.
@en
P356
P1476
Preclinical and clinical development of cyclin-dependent kinase modulators.
@en
P2093
A M Senderowicz
E A Sausville
P304
P356
10.1093/JNCI/92.5.376
P407
P577
2000-03-01T00:00:00Z